Monograph
J07AP03 - Typhoid, Purified Polysaccharide Antigen |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the typhoid, purified polysaccharide antigen vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Purified Vi capsular polysaccharide of Salmonella typhi
Therapeutic characteristics
The typhoid, purifies polysaccharide antigen vaccine is indicated for active immunization against typhoid fever caused by Salmonella enterica serovar typhi in adults and children 2 years of age or older.
It is administered intramuscularly or subcutaneously as a single dose. Repeated vaccination every three years may be indicated for subjects at risk from typhoid fever.
Metabolism and pharmacokinetics
The typhoid polysaccharide vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 2 patients with acute porphyria.
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Typhim. (Last edition: January 2015).
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
Denmark
Norway
Luxembourg
Iceland
Finland
Latvia© NAPOS 2024